The Lancet is a great journal. She has published there before. Doesn't look like we'll get the MRI results that the trimesta investors want so much though - at least that is my interpretation of this statement from the UCLA MS page: "In our recently completed multicenter trial of estriol in women with MS where we found significant beneficial effects on relapses and cognition, we acquired brain MRI scans. These MRI scans now need to be assessed for which region of the brain estriol treatment had the greatest effect impact on halting gray matter atrophy and with correlation to improvement in each disability."
I do like this statement: "A trial focusing on whether estriol treatment can improve cognition in not only RRMS, but also in progressive MS is needed. We have begun that trial, and it is ongoing at 4 sites across the U.S. Based on our results in the relapse trial, we know that this new trial is on target with regard to its optimal design and outcomes. In this trial, estriol treatment can be added on to other standard of care MS treatments (not just Copaxone, but also interferons or the new orals) or estriol can be used in people on no other MS treatments. The treatment duration is one year, and the primary outcome is cognitive testing."
And this statement makes me consider the possibility that the write up may show more positives for cognition than for RRMS - which is not in anyway a negative in the long term. The cognition trial is structured and active and they have a ton of data to support positive outcome. But...since the published study goals were RRMS based, SYN could be pummeled. "An unfortunate likelihood is that a treatment that optimally preserves or repairs leg strength may be different from a treatment that optimally preserves or repairs cognitive ability, which may, in turn, be different from one for vision. It is unlikely that there will be a silver bullet treatment to repair all disabilities in MS. The “one size fits all” approach is untenable given the known differences in neurological pathways."
Who knows? I don't. Could be a seriously positive response or could give bashers opportunity to pummel. But if SYN is in for a beating, the pain will be short lived. The cognition trial currently underway is the most positive path for Trimesta. When it is done - there will likely be lots of celebrating and lots of green accounts.
News 
Market Data 
Discover 
